Plain-English translation of NCT07674498 on ClinicalTrials.gov ↗ · Source last updated · Translation generated ·
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
The PRIME study is investigating whether a patient's immune system 'fitness'—not just their age—can predict how well they will respond to CAR-T cell therapy or bispecific antibodies for multiple myeloma. Researchers will collect blood samples before treatment starts to analyze the health and function of immune cells, then track how well the treatment works and what side effects occur.
Doctors have noticed that two older patients with similar myeloma sometimes respond very differently to the same treatment—one does great while the other struggles. This study aims to find biological markers in the blood that can predict who will benefit most and who is at higher risk for serious side effects, so treatment can be personalized.
You likely qualify if…
You likely don't qualify if…
You will have blood drawn once before your treatment begins, which researchers will analyze in detail to study your immune cells. After that, you'll simply continue your regular medical visits and treatments as planned—researchers will collect information from your medical records about how you respond to treatment and any side effects you experience. There are no extra visits or experimental treatments required; this is purely an observational study designed to learn from your care.
AI-generated summary from trial data · Jul 6, 2026 · Not medical advice
Belgium